The latest turmoil within Commissioner Marty Makary’s Food and Drug Administration , an alleged bribery scandal involving a high-level official, is no anomaly. The Sunday resignation of the Center for Drug Evaluation and Research’s Dr. George Tidmarsh, handpicked by Makary, reveals a pattern of obstructionism and chaos, as well as an antipathy toward green-lighting new therapies, within the nation’s top drug safety agency.

Aurinia Pharmaceuticals sued Tidmarsh for an exchange it claimed was a pay-to-play offer, as well as for disparaging its FDA-approved drug, voclosporin, in posts made on LinkedIn. The result was a $350 million loss of market value, all tied to a personal grudge between Tidmarsh and a former colleague.

Recommended Stories

Make America great again by restoring

See Full Page